BTG plc (LON:BTG) was upgraded by investment analysts at Numis Securities Ltd to a “buy” rating in a research report issued to clients and investors on Monday. The brokerage presently has a GBX 900 ($10.97) price target on the stock. Numis Securities Ltd’s target price would indicate a potential upside of 29.22% from the stock’s current price.
Several other analysts have also recently weighed in on BTG. Deutsche Bank AG reaffirmed a “buy” rating and issued a GBX 740 ($9.02) price target on shares of BTG plc in a report on Friday, June 24th. Stifel Nicolaus reissued a “buy” rating on shares of BTG plc in a report on Friday, June 24th. Jefferies Group raised their price objective on BTG plc from GBX 840 ($10.24) to GBX 860 ($10.48) and gave the company a “buy” rating in a report on Wednesday, June 29th. Finally, JPMorgan Chase & Co. decreased their price objective on BTG plc from GBX 800 ($9.75) to GBX 790 ($9.63) and set a “neutral” rating on the stock in a report on Friday, July 15th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of GBX 822.86 ($10.03).
BTG plc (LON:BTG) opened at 688.50 on Monday. The firm has a 50-day moving average price of GBX 641.72 and a 200 day moving average price of GBX 644.43. BTG plc has a 52 week low of GBX 504.00 and a 52 week high of GBX 739.50. The firm’s market capitalization is GBX 2.64 billion.
In related news, insider Soderstrom,Rolf sold 74,327 shares of the firm’s stock in a transaction that occurred on Thursday, July 21st. The stock was sold at an average price of GBX 676 ($8.24), for a total transaction of £502,450.52 ($612,371.14).
About BTG plc
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with MarketBeat.com's FREE daily email newsletter.